Carnitine HCl, Co-enzyme B12, Cyproheptadine orotate, Lysine Hydrochloride

Indications

Carnitine HCl, Co-enzyme B12, Cyproheptadine orotate, Lysine Hydrochloride is used for: L-CARNITINE
For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylcoa dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease
CYPROHEPTADINE
For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Carnitine HCl, Co-enzyme B12, Cyproheptadine orotate, Lysine Hydrochloride :

Mechanism of Action

L-CARNITINE
Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin c (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the l isomer of carnitine (sometimes called vitamin bt) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases
CYPROHEPTADINE
Cyproheptadine competes with free histamine for binding at ha-receptor sites. This antagonizes the effects of histamine on ha-receptors, leading to a reduction of the negative symptoms brought on by histamine ha-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for cyproheptadine's ability to stimulate appetite